NCT01167712 · OUTCOME

Median Duration of First Quartile Survival

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer · Source last updated 2026-05-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: The timeframe is from enrollment onto the study up to 3 years after enrollment

What was measured

First Quartile Overall Survival

Analysis population: Whole sample

Groups in this outcome

Arm I (Adjuvant Chemotherapy Suboptimally Debulked)

Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV

Arm II (Neoadjuvant Chemotherapy)

Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV Therapeutic Conventional Surgery: Undergo surgery

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Arm I (Adjuvant Chemotherapy Suboptimally Debulked)	346
Arm II (Neoadjuvant Chemotherapy)	346

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Arm I (Adjuvant Chemotherapy Suboptimally Debulked)	23.2	Not reported	20.1	26.3	Not reported
Arm II (Neoadjuvant Chemotherapy)	24	Not reported	19.8	26.0	Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

ci Lower Limit
.72
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.23
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
param Type
Hazard Ratio (HR)
param Value
.94

Complete source fields

analyses

ci Lower Limit
.72
ci Num Sides
TWO_SIDED
ci Pct Value
95
ci Upper Limit
1.23
group Ids
OG000
OG001
non Inferiority Type
SUPERIORITY
param Type
Hazard Ratio (HR)
param Value
.94

classes

categories
measurements
group Id
OG000
lower Limit
20.1
upper Limit
26.3
value
23.2
group Id
OG001
lower Limit
19.8
upper Limit
26.0
value
24

denoms

counts
group Id
OG000
value
346
group Id
OG001
value
346
units
Participants

description

First Quartile Overall Survival

dispersion Type

95% Confidence Interval

groups

description
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV
id
OG000
title
Arm I (Adjuvant Chemotherapy Suboptimally Debulked)
description
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4. Bevacizumab: Given IV Carboplatin: Given IV Computed Tomography: Correlative studies Paclitaxel: Given IV Therapeutic Conventional Surgery: Undergo surgery
id
OG001
title
Arm II (Neoadjuvant Chemotherapy)

param Type

MEDIAN

population Description

Whole sample

reporting Status

POSTED

time Frame

The timeframe is from enrollment onto the study up to 3 years after enrollment

title

Median Duration of First Quartile Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice